Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.
Breccia
Massimo
M
Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy. breccia@bce.uniroma1.it
Loglisci
Giuseppina
G
Salaroli
Adriano
A
Cannella
Laura
L
Santopietro
Michelina
M
Alimena
Giuliana
G
D001565:Benzoates / Q000627:therapeutic use*; D001803:Blood Transfusion; D000077588:Deferasirox; D041905:Erythroid Cells / Q000187:drug effects*; D005293:Ferritins / Q000097:blood; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000628:therapy; D014230:Triazoles / Q000627:therapeutic use*
D001565:Benzoates; D006454:Hemoglobins; D014230:Triazoles; D005293:Ferritins; D000077588:Deferasirox